OTCM
TRVN
Market cap10kUSD
Oct 08, Last price
0.01USD
1D
0.00%
1Q
8.11%
Jan 2017
-100.00%
IPO
-100.00%
Name
Trevena Inc
Chart & performance
P/E
—
P/S
0.00
EPS
—
Div yield, %
—
Shrs. gr., 5y
-24.14%
Rev. gr., 5y
-11.43%
Revenues
3m
P
Net income
-40m
L-24.93%
CFO
-33m
L-35.83%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Trevena, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing innovative pharmaceutical solutions for individuals suffering from central nervous system disorders. Its pipeline features several promising drug candidates: OLINVYK (Oliceridine) injection: A G protein-biased mu-opioid receptor (MOR) ligand engineered to manage acute pain ranging from moderate to severe. TRV027: Aimed at addressing acute lung injury, which contributes to acute respiratory distress syndrome (ARDS) and abnormal blood clotting in patients with COVID-19. TRV250: A G protein-biased delta-opioid receptor agonist under development for the treatment of acute migraine. TRV734: A small molecule G protein-biased MOR ligand designed for the management of both moderate-to-severe acute and chronic pain. TRV045: An innovative S1P modulator focused on providing relief for chronic pain. The company has also established a partnership with Imperial College London to investigate TRV027's potential in patients afflicted with COVID-19. Trevena, Inc., founded in 2007, operates from its headquarters in Chesterbrook, Pennsylvania.
Key people
President, Chief Executive Officer, Director · since 2018
Barry Shin
Chief Financial Officer · since 2019
Mark A Demitrack
Senior Vice President and Chief Medical Officer · since 2018
Yacoub Habib
Senior Vice President - Business Development and Corporate Planning · since 2015
David Soergel
Senior Vice President - Clinical Development , Chief Medical Officer
Robert T. Yoder
Senior Vice President and Chief Business Officer · since 2018
Chief Administrative Officer, Senior Vice President, General Counsel, Secretary · since 2016
Director · since 2018
Director · since 2018
Independent Director · since 2013
Independent Director · since 2014
Independent Director · since 2014
Independent Director · since 2014
Legal address
C/O Corporation Service Company
2711 Centerville Road
Suite 400
Wilmington, DE 19808
US
2711 Centerville Road
Suite 400
Wilmington, DE 19808
US
Headquarters
1018 West 8th Avenue
Suite A
King of Prussia, PA 19406
US
Suite A
King of Prussia, PA 19406
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||